Citations

Clear

11 citation(s) found for "Scheffler, Björn".

Quality and Readability of Websites on Tongue Base Procedures for Pediatric Obstructive Sleep Apnea
Rasmussen, Nathan , Mecham, Jeffrey C. , Scheffler, Patrick , Rasmussen, Nathan G

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/wjo2.70120 | PMID 42500074 Get It

ABSTRACT Objectives Tongue base obstruction is a cause of persistent sleep apnea after adenotonsillectomy in pediatric patients. The internet is the most used tool by patients for gathering healthcare information. This study aims to assess the quality and readability of websites directed to patients regarding tongue base procedures for pediatric obstructive sleep apnea. Methods Queries for the terms “lingual tonsillectomy,” “posterior midline glossectomy,” “tongue reduction,” “tongue base suspension,” and “hypoglossal nerve stimulator” were entered into Google on September 11, 2023. Thirty sites were pulled for each, and up to 10 sites per query meeting inclusion criteria were included for analysis. The DISCERN tool was used to evaluate quality. Flesch Reading Ease Score (FRES) and Flesch–Kincaid Grade Level (FKGL) were used to measure readability. Sites were analyzed for mention of pediatrics. Results Thirty‐five unique sites were analyzed. The mean DISCERN score was 44.7 (range 28.5–64.0) or “fair.” The mean FRES was 46.3 (range 9.6–66.6) and FKGL 11.5 (range 7.4–19.2), indicating college and 12th‐grade reading levels. Only 8/35 sites mentioned pediatrics. The average number per query of relevant sites directed towards patients on the first search engine page was 3.6. Despite tongue base procedures being relevant to pediatrics, only one in five sites mentioned children. Conclusion Websites directed at patients regarding tongue base procedures are of “fair” quality and at readability grade levels far above what is recommended. The majority of sites available for tongue base procedures are geared to professionals rather than patients. This study demonstrates a need for high‐quality information for patients about these procedures.
Cost impact of balloon guide catheter with mechanical thrombectomy for acute ischemic stroke: Analysis from the United States, Canada, and seven European countries
Makalanda, Levansri , Mortimer, Alex , González, Eva María , Maheswaran, Hendramoorthy , Scheffler, Shanti , Kottenmeier, Emilie , Brinjikji, Waleed , Gonzalez-Diaz, Eva , Kottenmeier, Emilie

Mayo Clinic

Interventional Neuroradiology | July 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251359730 | PMID 40702882 Get It

Background Balloon guide catheters (BGCs) are adjunctive devices that may be used during mechanical thrombectomy (MT) to induce flow arrest and improve clot retrieval and reperfusion outcomes for acute ischemic stroke. As the cost-effectiveness of BGC use remains uncertain, this study assessed short- and long-term direct healthcare costs associated with BGC use versus standard guide catheters (SGC) during MT. Methods A decision tree model estimated the short-term costs (index hospitalization), long-term costs (one year after index hospitalization), and total costs for patients undergoing MT + BGC versus MT + SGC from a healthcare system perspective in the United States (US), Canada, United Kingdom (UK), Sweden, Germany, Italy, Spain, Belgium, and The Netherlands. Average device costs were sourced from public tender prices and market research data. Weighted average healthcare costs for modified Rankin Scale scores were sourced from published literature for the respective countries. A 2024 meta-analysis supporting improved outcomes with BGC provided input parameters to model treatment effects for BGC and SGC. Deterministic one-way and probabilistic sensitivity analyses evaluated the robustness of model parameters and accounted for uncertainty. Results Across all countries, long-term and total per-patient costs were lower with MT + BGC, yielding total per-patient cost savings of $6297 (US), CAD 3006 (Canada), £1828 (UK), 28,950 kr (Sweden), €1077 (Germany), €709 (Italy), €3678 (Spain), €2259 (Belgium), and €3344 (The Netherlands). The probability of MT + BGC yielding cost savings ranged 0.356–0.911 (short term), 0.962–0.975 (long term), and 0.838–0.935 (total costs). While long-term and total costs consistently favored MT + BGC, short-term cost savings showed more variability across countries. Conclusion This study demonstrates that BGC use is associated with total one-year per-patient cost savings for inpatient and postdischarge stroke care across the US, Canada, and seven European healthcare systems. Balloon guide catheters can potentially reduce post-stroke care costs and should be considered more broadly, despite the additional cost incurred by the device.
The economic impact of stent retriever selection for acute ischemic stroke: a cost analysis of MASTRO I from the healthcare system perspective of the United States, Canada and eight European countries
Andersson, Tommy , Nordmeyer, Hannes , Brinjikji, Waleed , Kottenmeier, Emilie , Kabiri, Mina , Scheffler, Shanti , Brouwer, Patrick A. , Mirza, Mahmood , Zaidat, Osama O. , Andersson, Tommy , Brouwer, Patrick , Kottenmeier, Emilie

Mayo Clinic

Journal of Comparative Effectiveness Research | February 17, 2025 | Volume: 14 | Issue: 3 | Pages: No page available

10.57264/cer-2024-0216 | PMID 39957470 Get It

Aim: According to the results of the MASTRO I living systematic review and meta-analysis, use of the EmboTrap Revascularization ® Device in the treatment of acute ischemic stroke (AIS) results in higher rates of good functional outcomes (90-day modified Rankin Scale [mRS] 0–2) compared with use of the Trevo ® Retriever or the Solitaire™ Revascularization Device. The aim of this analysis was to assess the potential economic impact of achieving improved functional outcomes for three commonly used stent retrievers (SRs) in the treatment of AIS. Methods: An economic model with short-term and long-term costs, representing a healthcare system perspective was developed using a decision tree to simulate a cohort of 1000 hypothetical patients treated for AIS with mechanical thrombectomy (MT) using EmboTrap, Trevo or Solitaire SRs. Based on the proportion of patients who achieved a 90-day mRS score of 0–2 or 3–5 for each device reported in MASTRO I (excluding patients not surviving after 90 days), this model estimated per-patient costs and the associated incremental cost savings. Results are reported from the healthcare system perspective in the US, Canada, the UK, Sweden, Germany, France, Italy, Spain, Belgium and The Netherlands. Results: Across all ten countries, the use of EmboTrap during MT was associated with the lowest short-term (ranging from €8412 in Italy to $66,525 in the US), long-term (ranging from €5249 in Italy to $25,757 in the US) and total (ranging from €13,661 in Italy to $92,282 in the US) per-patient costs. The total per-patient cost was higher with Trevo (ranging from €14,601 in Italy to $97,487 in the US) and Solitaire (ranging from €14,840 in Italy to $98,814 in the US). Cost savings were highest when comparing EmboTrap versus Solitaire, followed by EmboTrap versus Trevo, with Trevo versus Solitaire having the smallest cost savings. Results of sensitivity and scenario analyses supported the robustness of the base-case results. Conclusion: Across the ten countries, treating patients with AIS with EmboTrap resulted in lower short-term, long-term and total costs to the payer. With rising healthcare costs and limited hospital budgets, these results suggest EmboTrap proves to be an evidence-based economical choice of SR for hospitals and healthcare systems.
Hypoglossal Nerve Stimulation Outcomes in Pediatric Trisomy 21 Patients with Overweight or Obesity
Mecham, Jeffrey C. , Gibbs, H G , House, Trenton , Scheffler, Patrick , Gibbs, Hannah, Gibbs, Hannah M.

Mayo Clinic

The Laryngoscope | November 9, 2024 | Volume: 135 | Issue: 3 | Pages: 1223-1226

10.1002/lary.31832 | PMID 39520257 Get It

Objectives To assess the impact of body mass index (BMI) on hypoglossal nerve stimulator (HNS) implantation outcomes in pediatric patients with Down syndrome (DS). We compare outcomes of HNS implantation when comparing children based on overweight or obese status. Methods Retrospective cohort study of patients at a single tertiary pediatric hospital who underwent HNS implantation between 2022 and 2024. Patients with DS under 21 years of age at time of implantation were included. One child with Wolf‐Hirschhorn syndrome was also included. The main outcome measured was reduction in apnea‐hypopnea index (AHI). Results Twenty patients were implanted with HNS during the study period. Eleven patients were implanted with a BMI considered overweight and 8 patients with a BMI considered obese. No significant correlation was found between BMI percentile and AHI reduction ( r = 0.06, p = 0.8). No significant differences were found between obese and non‐obese groups for preoperative AHI, postoperative AHI, or AHI reduction. Both groups responded favorably to HNS therapy with AHI reduction of 83.8% in obese patients and 81.9% in non‐obese patients. Conclusion We demonstrate no difference in postoperative AHI outcomes when comparing patients with obesity defined as BMI >95th percentile compared to those without. Level of Evidence 3 Laryngoscope , 135:1223–1226, 2025
Revised Classification of Inner Ear Schwannomas
Lloyd, Simon , Freeman, Simon , Kösling, S., Biggs, Nigel, Gubbels, Samuel P., Hess-Erga, Jeanette , Lohse, Christine M. , Marinelli, John P. , Micco, Riccardo Di , Nassiri, Ashley M. , Scheffler, Jonas , Cayé‐Thomasen, Per , Carlson, Matthew L., Plontke, Stefan K. , Arnoldner, Christoph , Borsetto, Daniele , Koo, Ja‐Won , Rahne, Torsten , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | October 30, 2024 | Volume: 46 | Issue: 1 | Pages: 3-9

10.1097/mao.0000000000004363 | PMID 39473303 Get It

ABSTRACT Over the past two decades, there has been increasing interest in the diagnosis and management of schwannomas of the inner ear including hearing rehabilitation with cochlear implants. However, tumor nomenclature and classification within the literature have been variable and oftentimes cumbersome. The term “intralabyrinthine schwannoma” is in common use when describing these tumors but is a potential source of confusion given that people often use the term “labyrinth” or “labyrinthine” to refer to the vestibular component of the inner ear only (i.e., labyrinthectomy or the translabyrinthine approach). During the Ninth Quadrennial Conference on Vestibular Schwannoma and Other Cerebellopontine Angle Lesions in Bergen, Norway, in May 2023, a multidisciplinary group of conference participants met and discussed issues pertaining to current terminology and classifications to enhance clarity and to reflect recent advances in tumor management and hearing rehabilitation. Although a variety of terms have been previously used to describe inner ear schwannomas, consensus was achieved on the term “inner ear schwannoma (IES)” to describe eighth nerve schwannomas of the cochlea, vestibule, or semicircular canals. Subgroups under this term comprise intravestibular, intracochlear, or intravestibulocochlear inner ear schwannomas (low complexity tumors), inner ear schwannomas with transfundal extension into the internal auditory canal but without modiolar involvement (intermediate complexity tumors), and inner ear schwannomas with transfundal extension with modiolar involvement (high complexity tumors). The details of the recommendations for an updated and simplified tumor nomenclature centered around tumor control and hearing rehabilitation with cochlear implantation are presented.
Country-level gender inequality is associated with structural differences in the brains of women and men
Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A. I. , Ringlein, Grace , Arango, Celso , Asmal, Laila , Bellgrove, Mark A. , Bernardo, Miquel , Billeke, Pablo , Bosch‐Bayard, Jorge , Busatto, Geraldo F. , Castro, Mariana N. , Chaim-Avancini, Tiffany , Compte, Albert , Costanzi, Monise , Dazzan, Paola , Fuente‐Sandoval, Camilo de la , Díaz‐Zuluaga, Ana M. , Duran, Fábio , Fittipaldi, Sol , Fornito, Alex , Freimer, Nelson B. , Gadelha, Ary , Gama, Clarissa Severino , Ramesh, Ranjini Garani , García‐Rizo, Clemente , Campo, Cecilia González , González‐Valderrama, Alfonso , Holla, Bharath , Ibáñez, Agustín , Ivanovic, Daniza , Jackowski, Andrea Parolin , Löchner, Christine , López‐Jaramillo, Carlos , Massuda, Raffael , McGuire, Philip , Murray, Robin , Özerdem, Ayşegül , Pan, Pedro Mário , Parellada, Mara , Phahladira, Lebogan, Ramírez-Mahaluf, Juan Pablo , Reyes-Madrigal, Francisco , Roos, Annerine , Scheffler, Freda , Stein, Dan J. , Tepper, Ángeles , Ueno, Tsukasa, Undurraga, Juan , Valli, Isabel , Villarreal, Mirta F. , Yalın, Nefize , Zamorano, Francisco , Zanetti, Marcus V. , cVEDA, Pine, Daniel S. , Evans‐Lacko, Sara , Crossley, Nicolás , Murthy, Pratima , Chakrabarti, Amit , Basu, Debasish , Subodh, B. N., Singh, Lenin, Singh, Roshan Lourembam, Kalyanram, Kartik , Kartik, Kamakshi, Kurpad, Sunita Simon , Bharath, Rose Dawn , Orfanos, Dimitri Papadopoulos , Sharma, Eesha , Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A I , Benegal, Vivek , Bernardo, Miquel , Billeke, Pablo , Busatto, Geraldo F , Castro, Mariana N , Czepielewski, Leticia , de la Fuente-Sandoval, Camilo , Duran, Fabio L S , Fittipaldi, Sol , Fornito, Alex , Garani, Ranjini , Guinjoan, Salvador , Ibañez, Agustín , Ivanovic, Daniza , Lochner, Christine , Massuda, Raffael , Miyata, Jun , Mizrahi, Romina , Murray, Robin , Ramirez-Mahaluf, Juan P , Reis Marques, Tiago , Reyes-Madrigal, Francisco , Roos, Annerine , Salum, Giovanni , Stein, Dan J , Tepper, Angeles , Undurraga, Juan , Undurraga, Eduardo A , Valdes-Sosa, Pedro , Valli, Isabel , Zamorano, Francisco , Crossley, Nicolas A , López-Jaramillo, Carlos , Ozerdem, Aysegul , Yalin, Nefize , Zugman, André , Seidlitz, Jakob , Arnatkevičiūtė, Aurina , Bressan, Rodrigo A. , Forti, Marta Di , Díaz‐Caneja, Covadonga M. , Plessis, Stefan S. du , León-Ortíz, Pablo , Luckhoff, Hilmar Klaus , Phahladira, Lebogang , Reckziegel, Ramiro de Freitas Xavier , Rosa-Neto, Pedro , Serpa, Maurício Henriques , Winton‐Brown, Toby , cVEDA, Winkler, Anderson M. , Kartik, Kamakshi , Kumaran, Kalyanaraman , Krishnaveni, Ghattu Vedamurthy , Kuriyan, Rebecca , Barker, Gareth J. , Desrivières, Sylvane , Purushottam, Meera , Hickman, Matthew , Heron, Jon , Toledano, Mireille B. , Vaidya, Nilakshi

Mayo Clinic

Proceedings of the National Academy of Sciences | May 8, 2023 | Volume: 120 | Issue: 20 | Pages: No page available

10.1073/pnas.2218782120 | PMID 37155867 Get It

Gender inequality across the world has been associated with a higher risk to mental health problems and lower academic achievement in women compared to men. We also know that the brain is shaped by nurturing and adverse socio-environmental experiences. Therefore, unequal exposure to harsher conditions for women compared to men in gender-unequal countries might be reflected in differences in their brain structure, and this could be the neural mechanism partly explaining women’s worse outcomes in gender-unequal countries. We examined this through a random-effects meta-analysis on cortical thickness and surface area differences between adult healthy men and women, including a meta-regression in which country-level gender inequality acted as an explanatory variable for the observed differences. A total of 139 samples from 29 different countries, totaling 7,876 MRI scans, were included. Thickness of the right hemisphere, and particularly the right caudal anterior cingulate, right medial orbitofrontal, and left lateral occipital cortex, presented no differences or even thicker regional cortices in women compared to men in gender-equal countries, reversing to thinner cortices in countries with greater gender inequality. These results point to the potentially hazardous effect of gender inequality on women’s brains and provide initial evidence for neuroscience-informed policies for gender equality.
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers
Hogenson, Tara L. , Phillips, William J. , Toruner, Merih Deniz , Li, Jing , Horn, Isaac P. , Kennedy, Devin J. , Almada, Luciana L. , Marks, David L. , Törüner, Murat , Sigafoos, Ashley N. , Koenig-Kappes, Amanda N., Olson, Rachel , Tolosa, Ezequiel J. , Bleeker, Jonathan , Barrett, Michael T. , Boyum, James H. , Kipp, Benjamin R. , Hanson, Temperance J. Scheffler, Petersen, Gloria M. , Dasari, Surendra , Oberg, Ann L. , Truty, Mark J. , Levy, Michael J. , Zhu, Mojun, Billadeau, Daniel D. , Adjei, Alex A. , Dusetti, Nelson , Iovanna, J., Bekaii‐Saab, Tanios , Fernández-Zapico, Martín E. , Toruner, Merih D., Doles, Jason D. , Bekaii-Saab, Tanios S , Toruner, Merih D , Xie, Hao , Phillips, William J. , Carr, Ryan M , Koenig-Kappes, A., Zhang, Cheng , Li, Hu , Mahipal, Amit , Hubbard, Joleen M. , Graham, Rondell P. , Wee, Wen

Mayo Clinic

JCI Insight | October 18, 2022 | Volume: 7 | Issue: 22 | Pages: No page available

10.1172/jci.insight.158060 | PMID 36256477 Get It

BACKGROUND A patient-derived organoid (PDO) platform may serve as a promising tool for translational cancer research. In this study, we evaluated PDO’s ability to predict clinical response to gastrointestinal (GI) cancers. METHODS We generated PDOs from primary and metastatic lesions of patients with GI cancers, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and cholangiocarcinoma. We compared PDO response with the observed clinical response for donor patients to the same treatments. RESULTS We report an approximately 80% concordance rate between PDO and donor tumor response. Importantly, we found a profound influence of culture media on PDO phenotype, where we showed a significant difference in response to standard-of-care chemotherapies, distinct morphologies, and transcriptomes between media within the same PDO cultures. CONCLUSION While we demonstrate a high concordance rate between donor tumor and PDO, these studies also showed the important role of culture media when using PDOs to inform treatment selection and predict response across a spectrum of GI cancers. TRIAL REGISTRATION Not applicable. FUNDING The Joan F. & Richard A. Abdoo Family Fund in Colorectal Cancer Research, GI Cancer program of the Mayo Clinic Cancer Center, Mayo Clinic SPORE in Pancreatic Cancer, Center of Individualized Medicine (Mayo Clinic), Department of Laboratory Medicine and Pathology (Mayo Clinic), Incyte Pharmaceuticals and Mayo Clinic Hepatobiliary SPORE, University of Minnesota-Mayo Clinic Partnership, and the Early Therapeutic program (Department of Oncology, Mayo Clinic).
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement
Sidell, Douglas R. , Balakrishnan, Karthik , Best, Simon R. , Zur, Karen B. , Buckingham, Julia C., Alarcón, Alessandro de , Baroody, Fuad M. , Bock, Jonathan M. , Boss, Emily F. , Bower, Charles M. , Clarke, Jeffrey , Clarke, Kevin D., Cocciaglia, Alejandro , Cotton, Robin T., Cuestas, Giselle , Davis, Kara L. , Defagó, Victor, Dikkers, Frederik G. , Dossans, Ines, Guerra, Walter Florez , Fox, Elizabeth , Friedman, Aaron D. , Grant, Nazaneen N. , Hogikyan, Norman D. , Johnson, Kaalan , Johnson, Liane B. , Johnson, Romaine F. , Kelly, Peggy, Klein, Adam M. , Lawlor, Claire M. , Levy, Alejandro G., Licameli, Greg R. , Long, Steve, Manrique, Dayse , McMurray, J. Scott , Meister, Kara D. , Messner, Anna H. , Möhr, Michael , Mortelliti, Anthony J., Novakovic, Daniel , Ongkasuwan, Julina , Piersiala, Krzysztof , Prager, Jeremy D. , Pransky, Seth M. , Raynor, Tiffany , Rodríguez, Hugo, Rodríguez, Verónica P., Scatolini, María Laura , Scheffler, Patrick , Smith, David F. , Smith, Lee P., Smith, Marshall E. , Smith, Richard J. , Sorom, Abraham, Steinberg, Amalia, Stith, John A., Thompson, Dana M. , Thompson, Jerome W. , Varela, Patricio, White, David R. , Wineland, Andre , Yang, Christina J. , Zdanski, Carlton J. , Derkay, Craig S. , Zur, Karen , de Alarcón, Alessandro , Campisi, Paolo , Friedman, Aaron D , Hamdi, Osama , Johnson, Romaine F , Leboulanger, Nicolas , Meister, Kara D , Novakovic, Daniel , Ongkasuwan, Julian , Prager, Jeremy D , Rinkel, Rico N P M , Smith, David F , Wineland, Andre M , Sidell, Douglas R , Davis, Kara L , Balakrishnan, Karthik , Buckingham, Julia, Chen, Sharon , Hamdi, Osama A. , Leboulanger, Nicolas , Lam, Derek J. , Long, Steve, Lott, David G. , Mudd, Pamela A. , Peer, Shazia , Preciado, Diego A. , Russell, John

Mayo Clinic

The Laryngoscope | January 8, 2021 | Volume: 131 | Issue: 6 | Pages: No page available

10.1002/lary.29343 | PMID 33405268 Get It

Objectives/HypothesisThe purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.Study DesignDelphi method‐based survey series.MethodsA multidisciplinary, multi‐institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work‐up.ResultsThe international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).ConclusionThis consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best‐practice applications of systemic bevacizumab for patients with early‐onset or less‐severe disease phenotypes.Level of Evidence5 Laryngoscope, 131:E1941–E1949, 2021
Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients
Finsterwalder, Sofia , Vlegels, Naomi , Caballero, Miguel Ángel Araque, Georgakis, Marios K. , (DIAN), Dominantly Inherited Alzheimer Network, Graff‐Radford, Neill R. , Salloway, Stephen , Oh, Hwamee , Chhatwal, Jasmeer P. , group, DELCODE study, Jessen, Frank , Düzel, Emrah , Dobisch, Laura, Metzger, Coraline D., Peters, Oliver , Incesoy, Enise I. , Priller, Josef , Spruth, Eike Jakob , Schneider, Anja , Fließbach, Klaus , Büerger, Katharina , Janowitz, Daniel , Kilimann, Ingo , Laske, Christoph , Buchmann, Martina, Heneka, Michael T. , Spottke, Annika , Roy, Nina, Ertl‐Wagner, Birgit , (ADNI), Alzheimer's Disease Neuroimaging Initiative, group, Utrecht VCI study, Seo, Sang Won , Na, Duk L. , Kim, Hee Jin, Ewers, Michael , Xiong, Chengjie , Schmidt, Reinhold , Pasternak, Ofer , Dichgans, Martin , Biessels, Geert Jan , Duering, Marco , Dichgans, Martin , Xiong, Chengjie , Gesierich, Benno G. , Weaver, Nick A. , Franzmeier, Nicolai , Konieczny, Marek J., Koek, Huiberdina L. , (DIAN), Dominantly Inherited Alzheimer Network, Karch, Celeste M. , Allegri, Ricardo , group, DELCODE study, Teipel, Stefan Johannes , Brosseron, Frederic , Scheffler, Klaus , (ADNI), Alzheimer's Disease Neuroimaging Initiative, group, Utrecht VCI study, Kim, Yeshin , Kim, Hee Jin, Jang, Hyemin , Biessels, Geert Jan , Duering, Marco

Mayo Clinic

Alzheimer's & Dementia | August 25, 2020 | Volume: 16 | Issue: 11 | Pages: 1504-1514

10.1002/alz.12150 | PMID 32808747 Get It

AbstractIntroductionMicrostructural alterations as assessed by diffusion tensor imaging (DTI) are key findings in both Alzheimer's disease (AD) and small vessel disease (SVD). We determined the contribution of each of these conditions to diffusion alterations.MethodsWe studied six samples (N = 365 participants) covering the spectrum of AD and SVD, including genetically defined samples. We calculated diffusion measures from DTI and free water imaging. Simple linear, multivariable random forest, and voxel‐based regressions were used to evaluate associations between AD biomarkers (amyloid beta, tau), SVD imaging markers, and diffusion measures.ResultsSVD markers were strongly associated with diffusion measures and showed a higher contribution than AD biomarkers in multivariable analysis across all memory clinic samples. Voxel‐wise analyses between tau and diffusion measures were not significant.DiscussionIn memory clinic patients, the effect of SVD on diffusion alterations largely exceeds the effect of AD, supporting the value of diffusion measures as markers of SVD.
Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma
Zegar, Tim, Weiser, Tim, Hamdan, Feda H. , Berger, Benedict‐Tilman , Balourdas, Dimitrios-Ilias , Ladigan, Swetlana, Cheung, Phyllis F. , Liffers, Sven‐Thorsten, Scheffler, Björn , Joerger, Andreas C. , Hahn, Stephan A. , Johnsen, Steven A. , Knapp, Stefan , Siveke, Jens T. , Ladigan, Swetlana , Siveke, Jens , Johnsen, Steven A , Hahn, Stephan A , Zhang, Xin , Lucas, Romain, Trajkovic‐Arsic, Marija

Mayo Clinic

International Journal of Cancer | June 29, 2020 | Volume: 147 | Issue: 10 | Pages: 2847-2861

10.1002/ijc.33137 | PMID 32599645 Get It

AbstractPancreatic ductal adenocarcinoma (PDAC) is resistant to virtually all chemo‐ and targeted therapeutic approaches. Epigenetic regulators represent a novel class of drug targets. Among them, BET and HDAC proteins are central regulators of chromatin structure and transcription, and preclinical evidence suggests effectiveness of combined BET and HDAC inhibition in PDAC. Here, we describe that TW9, a newly generated adduct of the BET inhibitor (+)‐JQ1 and class I HDAC inhibitor CI994, is a potent dual inhibitor simultaneously targeting BET and HDAC proteins. TW9 has a similar affinity to BRD4 bromodomains as (+)‐JQ1 and shares a conserved binding mode, but is significantly more active in inhibiting HDAC1 compared to the parental HDAC inhibitor CI994. TW9 was more potent in inhibiting tumor cell proliferation compared to (+)‐JQ1, CI994 alone or combined treatment of both inhibitors. Sequential administration of gemcitabine and TW9 showed additional synergistic antitumor effects. Microarray analysis revealed that dysregulation of a FOSL1‐directed transcriptional program contributed to the antitumor effects of TW9. Our results demonstrate the potential of a dual chromatin‐targeting strategy in the treatment of PDAC and provide a rationale for further development of multitarget inhibitors.